HOME >> MEDICINE >> NEWS
Phase II trial of anthrax vaccine to begin

Center for Vaccine Research needs volunteers for Phase II Trial of anthrax vaccine candidate

(Torrance, CA April 22, 2004) The UCLA Center for Vaccine Research, a leading research program at the Research and Education Institute (REI) at Harbor UCLA Medical Center, announced today that it has initiated a Phase II trial of a new anthrax vaccine, rPA102 (VaxGen, Inc.). The 13-month trial is taking place at 12 medical centers in the United States and is one of two studies of rPA102 initiated this year under a multi-year, $80.3 million U.S. government contract to VaxGen, Inc. from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

VaxGen, Inc. began developing rPA102 to address the need for an anthrax vaccine that has an improved safety profile and a more practical dosing schedule compared to the existing licensed anthrax vaccine. rPA is a synthetic protein vaccine that induces antibodies that are designed to prevent illness by neutralizing anthrax toxins. rPA102 cannot cause anthrax infection. The goal of this study is to determine the optimal formulation of the rPA vaccine that will provide an early and protective immune response.

Healthy adults, 18 to 55 years of age, who have not received an anthrax vaccine and have not been exposed to anthrax, are needed to participate in this study. Participants will need to be available for 14 visits to the clinic (Torrance) over a one-year period. Participants will be compensated up to $700 for completion of study visits.

For further information on how to take part in this trial, please call 1-800-637-8860.


'"/>

Contact: Susan Partridge, BSN, MBA
partridge@humc.edu
310-781-3630
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
22-Apr-2004


Page: 1

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
3. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
4. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
5. Penn researchers announce results of Phase I trial using combretastatin drug
6. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
7. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
8. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
9. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
10. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer
11. Positive Results Of Pivotal Phase III Trial With ENBREL In Patients With Early, Active Rheumatoid Arthritis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... ... 19, 2019 , ... Marking a key milestone in the ... on Wednesday will lift into place the final steel beam at AHN ... year. , The nearly 79,000-square-foot facility – located at 6321 Route 30, Greensburg, ...
(Date:2/19/2019)... HILLS, Calif. (PRWEB) , ... February 19, 2019 ... ... Wachler Vision Institute, Brian Boxer Wachler, MD, has launched the first ever supplement ... that can lead to severe to severe vision loss. The supplement, KC Defense, ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... with town halls across the country , A partnership between Liberty University and ... crisis, continues with its next town hall event on Tuesday, February 19, at ...
(Date:2/19/2019)... JACKSONVILLE, Fla. (PRWEB) , ... February 19, 2019 ... ... professors say yes! , “Nova Filtration is based in The Villages FL proudly ... success in our new franchised Territory in the greater Jacksonville area selling and ...
(Date:2/19/2019)... ... February 19, 2019 , ... Dr. Lombardi is ... Oncology Institute of Hope and Innovation. , Dr. Lombardi completed his undergraduate in ... received his medical degree from the University of Rochester School of Medicine. He ...
Breaking Medicine News(10 mins):
(Date:2/16/2019)... ... February 15, 2019 , ... ... Allison Marlow of Perio-Implant Care are urging patients to take their oral health ... cancers, diabetes, Alzheimer's and dementia, and risk of pre-term birth, there is plenty ...
(Date:2/16/2019)... ... 15, 2019 , ... Dr. Lucas Bryant, board-certified Face expert ... Haute Beauty Network, well known for their exclusivity, and luxurious lifestyle, is privileged ... newest addition to the Haute Living partnership. , Haute Beauty offers a prominent ...
(Date:2/14/2019)... Colo. (PRWEB) , ... February 14, 2019 , ... ... Month , Lewis and Clark College Emeritus Professor of Education Gregory A. Smith ... They discuss the emergence of Brand Ambassador programs, a new phenomenon in the ...
Breaking Medicine Technology:
Cached News: